Download PDF
CC BY 4.0 · Surg J (N Y) 2021; 07(03): e195-e198
DOI: 10.1055/s-0041-1731634
Case Report

Synovial Sarcoma of Ethmoidal Sinus

Sapna Dhiman
1   Department of Otolaryngology-Head and Neck Surgery (ENT), Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
,
Sarita Negi
1   Department of Otolaryngology-Head and Neck Surgery (ENT), Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
,
Sandeep Moudgil
2   Department of Neuro-Radiology and Intervention, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
,
Jagdeep S. Thakur 
1   Department of Otolaryngology-Head and Neck Surgery (ENT), Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
,
Ramesh K. Azad
1   Department of Otolaryngology-Head and Neck Surgery (ENT), Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Synovial sarcoma is an aggressive soft tissue cancer of extremities mainly and rare in head and neck region, whereas rarest in ethmoidal sinus as only three cases have been reported till date.

Case Reports We managed two cases of synovial sarcoma who presented with nasal obstruction, epistaxis, and swelling around the nasofacial region. Endoscopic nasal biopsy and immunohistochemistry markers confirmed synovial sarcoma in both the cases. While one case was managed by surgery and chemoradiation, the second patient received two cycles of ifosfamide-based chemotherapy and succumbed after 6 weeks of diagnosis.

Conclusion Head and neck sarcomas are aggressive and carry a poor prognosis. Surgical resection with postoperative radiotherapy is the standard treatment. However, they have a high risk of recurrence and hence aggressive management and close follow-up is warranted for the optimal outcome.

Keywords

nose - ethmoid sinus - synovial sarcoma - tumor


Publication History

Received: 06 July 2020

Accepted: 14 April 2021

Article published online:
03 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (05) 277-300
    CrossrefPubMedGoogle Scholar
  • 2 Kraus DH, Dubner S, Harrison LB. et al. Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas. Cancer 1994; 74 (02) 697-702
    CrossrefPubMedGoogle Scholar
  • 3 Jain A, Saxena A, Meher R, Khurana N. Synovial sarcoma of the ethmoid sinus. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 135 (06) 453-455
    CrossrefPubMedGoogle Scholar
  • 4 Wong HT, Ho CY, Nazarina AR, Prepageran N. Synovial sarcoma of the ethmoidal sinus. J Laryngol Otol 2014; 128 (11) 1022-1023
    CrossrefPubMedGoogle Scholar
  • 5 Salcedo-Hernández RA, Lino-Silva LS, Luna-Ortiz K. Maxillary sinus sarcoma: epidemiological and clinicopathological experience of 25 years in a national reference cancer centre. Indian J Otolaryngol Head Neck Surg 2014; 66 (04) 359-364
    CrossrefPubMedGoogle Scholar
  • 6 Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995; 164 (01) 129-134
    CrossrefPubMedGoogle Scholar
  • 7 Bukachevsky RP, Pincus RL, Shechtman FG, Sarti E, Chodosh P. Synovial sarcoma of the head and neck. Head Neck 1992; 14 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 8 Mallen-St Clair J, Arshi A, Abemayor E, St John M. Factors associated with survival in patients with synovial cell sarcoma of the head and neck: an analysis of 167 cases using the SEER (Surveillance, Epidemiology, and End Results) database. JAMA Otolaryngol Head Neck Surg 2016; 142 (06) 576-583
    CrossrefPubMedGoogle Scholar
  • 9 Andrä C, Rauch J, Li M. et al. Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck. Radiat Oncol 2015; 10: 140
    CrossrefPubMedGoogle Scholar
  • 10 Hoffman HT, Robinson RA, Spiess JL, Buatti J. Update in management of head and neck sarcoma. Curr Opin Oncol 2004; 16 (04) 333-341
    CrossrefPubMedGoogle Scholar
  • 11 Colville RJ, Charlton F, Kelly CG, Nicoll JJ, McLean NR. Multidisciplinary management of head and neck sarcomas. Head Neck 2005; 27 (09) 814-824
    CrossrefPubMedGoogle Scholar
  • 12 Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov 2015; 5 (02) 124-134
    CrossrefPubMedGoogle Scholar
  • 13 Owosho AA, Estilo CL, Rosen EB, Yom SK, Huryn JM, Antonescu CR. A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. Oral Oncol 2017; 66: 46-51
    CrossrefPubMedGoogle Scholar
  • 14 Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM. Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck 2007; 29 (08) 731-740
    CrossrefPubMedGoogle Scholar
  • 15 Jones SE, Fleuren EDG, Frankum J. et al. ATR is a therapeutic target in synovial sarcoma. Cancer Res 2017; 77 (24) 7014-7026
    CrossrefPubMedGoogle Scholar
  • 16 Dallos M, Tap WD, D'Angelo SP. Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy 2016; 8 (09) 1073-1080
    CrossrefPubMedGoogle Scholar
  • 17 van der Graaf WT, Blay JY, Chawla SP. et al; EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379 (9829): 1879-1886
    CrossrefPubMedGoogle Scholar
  • 18 Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115 (15) 3537-3547
    CrossrefPubMedGoogle Scholar